Walgreens Boots Alliance (NASDAQ:WBA) Releases FY 2025 Earnings Guidance

Walgreens Boots Alliance (NASDAQ:WBA) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided earnings per share guidance of 1.400-1.800 for the period, compared to the consensus earnings per share estimate of 1.750. The company issued revenue guidance of $147.0 billion-$151.0 billion, compared to the consensus revenue estimate of $147.3 billion. Walgreens Boots Alliance also updated its FY25 guidance to $1.40-$1.80 EPS.

Walgreens Boots Alliance Stock Up 6.2 %

Shares of WBA stock opened at $11.07 on Thursday. Walgreens Boots Alliance has a 1 year low of $8.22 and a 1 year high of $27.05. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.31 and a current ratio of 0.65. The business’s fifty day moving average is $9.41 and its 200-day moving average is $13.22. The stock has a market cap of $9.56 billion, a PE ratio of -1.64, a price-to-earnings-growth ratio of 1.06 and a beta of 0.70.

Walgreens Boots Alliance (NASDAQ:WBA) last released its earnings results on Tuesday, October 15th. The pharmacy operator reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.36 by $0.03. Walgreens Boots Alliance had a positive return on equity of 12.63% and a negative net margin of 3.99%. The firm had revenue of $37.50 billion for the quarter, compared to analyst estimates of $35.75 billion. During the same period in the previous year, the company earned $0.67 earnings per share. Walgreens Boots Alliance’s revenue was up 5.9% compared to the same quarter last year. Equities analysts expect that Walgreens Boots Alliance will post 2.85 earnings per share for the current fiscal year.

Analyst Ratings Changes

WBA has been the topic of several recent research reports. TD Cowen decreased their price target on shares of Walgreens Boots Alliance from $22.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, September 12th. UBS Group decreased their target price on Walgreens Boots Alliance from $17.00 to $12.00 and set a “neutral” rating on the stock in a report on Wednesday, July 3rd. Evercore ISI boosted their target price on Walgreens Boots Alliance from $7.50 to $10.00 and gave the stock an “in-line” rating in a research report on Wednesday. Royal Bank of Canada decreased their price target on Walgreens Boots Alliance from $22.00 to $13.00 and set a “sector perform” rating for the company in a research report on Tuesday, July 2nd. Finally, Morgan Stanley cut their price objective on Walgreens Boots Alliance from $9.00 to $7.00 and set an “underweight” rating on the stock in a report on Friday, October 11th. Four analysts have rated the stock with a sell rating, eight have assigned a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average price target of $13.54.

About Walgreens Boots Alliance

Walgreens Boots Alliance, Inc operates as a healthcare, pharmacy, and retail company in the United States, the United Kingdom, Germany, and internationally. It operates through three segments: U.S. Retail Pharmacy, International, and U.S. Healthcare. The U.S. Retail Pharmacy segment engages in operation of the retail drugstores, health and wellness services, specialty, and home delivery pharmacy services, which offers health and wellness, beauty, personal care and consumables, and general merchandise.